NuScale Power (SMR) stock jumps 13% today as nuclear shares rally — what’s driving the move
2 January 2026
1 min read

NuScale Power (SMR) stock jumps 13% today as nuclear shares rally — what’s driving the move

NEW YORK, Jan 2, 2026, 1:04 PM ET — Regular session

  • NuScale Power shares jumped about 13% in midday trading, outpacing the broader market.
  • Other nuclear-linked names also climbed, including Oklo and Nano Nuclear Energy.
  • Traders are watching next week’s U.S. labor-market data and the company’s next earnings timing.

Shares of NuScale Power Corp (NYSE:SMR) climbed on Friday, lifting the nuclear technology stock early in the first session of 2026. The shares were up 13.2% at $16.05, after touching $16.07, with about 17.6 million shares traded.

The move matters because NuScale sits in a pocket of the market where flows can dominate fundamentals for long stretches. Investors treat small modular reactor developers as a long-duration bet on future electricity demand, making the stocks sensitive to shifts in risk appetite.

Friday’s jump also stood out against a mixed tape, suggesting the bid was concentrated in theme trades rather than broad market momentum. Small caps edged up while large-cap and tech-heavy ETFs slipped.

Other nuclear and uranium-linked stocks moved higher in tandem. Oklo rose about 6.9%, Nano Nuclear Energy gained roughly 12.3%, and uranium miner Cameco added about 7.2%.

Nuclear operations also landed back in headlines overseas. Finnish operator Teollisuuden Voima said electricity production at its Olkiluoto 2 unit was interrupted after a fault during a software update triggered a “reactor trip” — an automatic shutdown designed to keep the plant safe. 1

Macro expectations remain a key swing factor for high-volatility growth stocks. “The next Fed Chair is probably going to be much more dovish than Jerome Powell,” said Dennis Dick, chief market strategist at Stock Trader Network, as investors looked ahead to next week’s U.S. labor-market data. 2

NuScale develops small modular reactors, or SMRs — smaller nuclear units designed to be built largely in factories and assembled into a full plant. The U.S. Nuclear Regulatory Commission approved NuScale’s 77-megawatt reactor design in 2025, clearing a major hurdle for its commercialization plans. 3

The company last updated investors on quarterly results on Nov. 6 and has not posted a new earnings release since then. Traders tend to focus on customer and financing updates alongside results because the company remains in the development-and-deployment phase. 4

NuScale’s investor events page currently lists no upcoming conferences. That leaves the next major scheduled catalyst as its next quarterly reporting cycle. 5

NuScale has not announced a date for fourth-quarter and full-year results, though market calendars currently project an early-March release. Investors will watch for updates on cash needs, funding plans and progress toward customer commitments. 6

With the stock trading in a wide intraday band, $16 has emerged as a near-term level traders are testing, while the prior close near $14 is the reference point for near-term support. Heavy volume points to active short-term positioning.

Stock Market Today

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
New York, Feb 7, 2026, 09:35 EST — Market closed. Roivant Sciences Ltd shares leapt on Friday after the company reported positive mid-stage results for its immune-modulating drug brepocitinib in a rare skin disease, and paired the readout with its quarterly financial update. The Nasdaq-listed stock closed up 22.4% at $25.82, leaving traders to gauge whether the move has legs when U.S. markets reopen on Monday, Feb. 9. It matters because Roivant is trying to turn a late-stage pipeline into approvals, and the market has been quick to reward biotechs that can show clean efficacy in controlled trials. The company
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
AMD stock jumps 8% in chip rebound — what investors are watching before Monday

AMD stock jumps 8% in chip rebound — what investors are watching before Monday

7 February 2026
AMD shares jumped 8.2% to $208.44 Friday, trading on heavy volume as chip stocks rebounded and the Dow closed above 50,000 for the first time. The Philadelphia Semiconductor Index rose 5.7% after Amazon’s AI spending plans lifted sector estimates. Nvidia’s CEO cited surging AI chip demand. AMD’s rally followed a weak revenue outlook earlier in the week.
Pentagon awards Lockheed $328.5 million Taiwan IRST pod contract as China drills keep island on alert
Previous Story

Pentagon awards Lockheed $328.5 million Taiwan IRST pod contract as China drills keep island on alert

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal
Next Story

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal

Go toTop